Sloboda D M, Moss T J, Gurrin L C, Newnham J P, Challis J R G
Canadian Institutes of Health Research Group in Fetal and Neonatal Health and Development, Departments of Physiology and Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada.
J Endocrinol. 2002 Jan;172(1):71-81. doi: 10.1677/joe.0.1720071.
Prenatal exposure to glucocorticoids is associated with alterations in fetal growth and endocrine function. However, few studies have examined the effects of clinically relevant doses of glucocorticoids on postnatal hypothalamic-pituitary-adrenal (HPA) function. To determine the effects of maternal or fetal betamethasone administration (0.5 mg/kg maternal or estimated fetal weight) on postnatal HPA function at 6 months and 1 year postnatal age, pregnant ewes were randomized into the following treatment groups: no treatment (n=6); maternal saline (n=6); single maternal betamethasone (M1) (n=6); repeated maternal betamethasone (M4) (n=6); fetal saline (n=5); single fetal betamethasone (n=6) and repeated fetal betamethasone (F4) (n=6). Single injections were given at 104 days of gestation and repeated injections at 104, 111, 118 and 125 days. Lambs were born spontaneously and the ACTH and cortisol responses to i.v. corticotropin-releasing hormone (CRH) (0.5 microg/kg) plus arginine vasopressin (AVP) (0.1 microg/kg) were measured at 6 months and 1 year postnatally. At 6 months postnatal age, neither maternal nor fetal prenatal betamethasone administration altered significantly the ACTH and cortisol responses to CRH+AVP. However, in animals at 1 year postnatal age, a previous single injection of betamethasone to the mother (M1) resulted in significantly elevated basal and stimulated cortisol levels (P<0.05), without significant change in the ACTH response. In contrast, betamethasone administration to the fetus resulted in significantly attenuated ACTH responses to CRH+AVP at 1 year compared with control animals (P<0.05), but these were not associated with any significant changes in basal or stimulated cortisol levels. All control animals exhibited a significant increase in peak ACTH responses to CRH+AVP between 6 months and 1 year postnatal age (P<0.05). After prenatal betamethasone (F4, M4) the difference in peak ACTH response between animals at 6 months and 1 year postnatal age was abolished. We conclude that in sheep between 6 months and 1 year postnatal age, HPA function undergoes developmental changes that are influenced by prenatal glucocorticoid exposure. Furthermore, the effects of glucocorticoid on postnatal HPA responses may vary according to the time in gestation that the steroid was administered, and whether it was given directly into the fetal or maternal compartment.
产前暴露于糖皮质激素与胎儿生长和内分泌功能的改变有关。然而,很少有研究探讨临床相关剂量的糖皮质激素对产后下丘脑 - 垂体 - 肾上腺(HPA)功能的影响。为了确定母体或胎儿给予倍他米松(0.5mg/kg母体或估计胎儿体重)对产后6个月和1岁时HPA功能的影响,将怀孕的母羊随机分为以下治疗组:不治疗(n = 6);母体生理盐水(n = 6);单次母体倍他米松(M1)(n = 6);重复母体倍他米松(M4)(n = 6);胎儿生理盐水(n = 5);单次胎儿倍他米松(n = 6)和重复胎儿倍他米松(F4)(n = 6)。在妊娠104天时给予单次注射,在104、111、118和125天时给予重复注射。羔羊自然分娩,并在产后6个月和1岁时测量促肾上腺皮质激素(ACTH)和皮质醇对静脉注射促肾上腺皮质激素释放激素(CRH)(0.5μg/kg)加精氨酸加压素(AVP)(0.1μg/kg)的反应。在产后6个月时,母体或胎儿产前给予倍他米松均未显著改变ACTH和皮质醇对CRH + AVP的反应。然而,在产后1岁的动物中,先前单次给母体注射倍他米松(M1)导致基础和刺激后的皮质醇水平显著升高(P < 0.05),而ACTH反应无显著变化。相比之下,给胎儿注射倍他米松导致在1岁时与对照动物相比,对CRH + AVP的ACTH反应显著减弱(P < 0.05),但这些与基础或刺激后的皮质醇水平的任何显著变化无关。所有对照动物在产后6个月至1岁之间对CRH + AVP的ACTH峰值反应均显著增加(P < 0.05)。产前给予倍他米松(F4,M4)后,产后6个月和1岁动物之间ACTH峰值反应的差异消失。我们得出结论,在产后6个月至1岁的绵羊中,HPA功能经历发育变化,这受到产前糖皮质激素暴露的影响。此外,糖皮质激素对产后HPA反应的影响可能因给予类固醇的妊娠时间以及是直接给予胎儿还是母体而有所不同。